Literature DB >> 3484964

Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma.

I Lecander, B Astedt.   

Abstract

A specific plasminogen activator inhibitor was isolated from the plasma of pregnant women by matrix-bound, cross reacting monoclonal antibodies against placental plasminogen activator inhibitor. The pregnancy plasma plasminogen activator inhibitor (PP-PA-I) was found to be immunologically different from the inhibitor produced by endothelial cells. Its molecular weight was 70 000 daltons. It formed complexes with urokinase (u-PA) and with plasminogen activator of the tissue type (t-PA), similar to those formed by the placental plasminogen activator inhibitor (PI-PA-I). It did not inhibit plasmin. For measuring PP-PA-I, an enzyme-linked immunosorbent assay (ELISA) was designed using monoclonal and polyclonal antibodies against the placental inhibitor. Concentrations of PP-PA-I increased successively during pregnancy, and fell sharply after delivery. This inhibitor could not be detected in normal non-pregnancy plasma. The results indicate that the inhibitor isolated from pregnancy plasma is responsible for the depressed fibrinolytic activity during pregnancy, and that the placenta is the source of the inhibitor.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3484964     DOI: 10.1111/j.1365-2141.1986.tb02925.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  The cost-benefit ratio of screening pregnant women for thrombophilia.

Authors:  Gian Luca Salvagno; Giuseppe Lippi; Massimo Franchini; Giovanni Targher; Martina Montagnana; Massimo Franchi; Gian Cesare Guidi
Journal:  Blood Transfus       Date:  2007-11       Impact factor: 3.443

2.  Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis.

Authors:  B Lyons-Giordano; D Loskutoff; C S Chen; G Lazarus; M Keeton; P J Jensen
Journal:  Histochemistry       Date:  1994-02

Review 3.  The plasmin-antiplasmin system: structural and functional aspects.

Authors:  Johann Schaller; Simon S Gerber
Journal:  Cell Mol Life Sci       Date:  2010-12-07       Impact factor: 9.261

Review 4.  The plasminogen-plasmin system in malignancy.

Authors:  H C Kwaan
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

Review 5.  Ischemic stroke and cerebral venous sinus thrombosis in pregnancy.

Authors:  Hannah J Roeder; Jean Rodriguez Lopez; Eliza C Miller
Journal:  Handb Clin Neurol       Date:  2020

6.  Differential protease expression by cutaneous squamous and basal cell carcinomas.

Authors:  A P Sappino; D Belin; J Huarte; S Hirschel-Scholz; J H Saurat; J D Vassalli
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

7.  Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney.

Authors:  A P Sappino; J Huarte; J D Vassalli; D Belin
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

8.  Tissue plasminogen activator, plasminogen activator inhibitor, and other parameters of fibrinolysis in the early stages of taurocholate acute pancreatitis in rats.

Authors:  G Rydzewska; S Kosidlo; A Gabryelewicz; A Rydzewski
Journal:  Int J Pancreatol       Date:  1992-06

Review 9.  Clinical disorders of fibrinolysis: a critical review.

Authors:  R B Francis
Journal:  Blut       Date:  1989-07

10.  Plasminogen activator-specific inhibitors produced by human monocytes/macrophages.

Authors:  A Wohlwend; D Belin; J D Vassalli
Journal:  J Exp Med       Date:  1987-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.